Related Experiment Video
Updated: Aug 30, 2025
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast
Yifan Ren1, Jialong Song1, Xinyi Li1
1Department of Histology, School of Medicine, Nankai University, Tianjin 300071, China.
Abstract:
Metastatic triple-negative breast cancer (mTNBC), a highly aggressive and malignant tumor, currently lacks an effective treatment. There has been some progress in the treatment of mTNBC with programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) immunotherapy in recent years. The combination of PD-1/PD-L1 inhibitors with other therapies is a noteworthy treatment strategy. Immunotherapy in combination with chemotherapy or small-molecule inhibitors still faces many challenges. Additionally, there are some new immunotherapy targets in development. We aimed to further evaluate the effectiveness and usefulness of immunotherapy for treating mTNBC and to propose new immunotherapy strategies. This review explains the rationale and results of existing clinical trials evaluating PD-1/PD-L1 inhibitors alone or in combination for the treatment of mTNBC. For patients with aggressive tumors and poor health, PD-1/PD-L1 inhibitors, either alone or in combination with other modalities, have proven to be effective. However, more research is needed to explore more effective immunotherapy regimens that will lead to new breakthroughs in the treatment of mTNBC.
Insights
Programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) immunotherapy shows promise for metastatic triple-negative breast cancer (mTNBC). While effective alone or combined, further research is needed for optimal treatment strategies.
Area of Science:
- Oncology
- Immunotherapy
- Medical Research
Background:
- Metastatic triple-negative breast cancer (mTNBC) is an aggressive malignancy with limited therapeutic options.
- Recent advancements include programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) immunotherapy.
Purpose of the Study:
- To evaluate the effectiveness of PD-1/PD-L1 inhibitors in mTNBC treatment.
- To explore novel immunotherapy strategies for mTNBC.
Main Methods:
- Review of existing clinical trials on PD-1/PD-L1 inhibitors in mTNBC.
- Analysis of combination therapies including chemotherapy and small-molecule inhibitors.
Main Results:
- PD-1/PD-L1 inhibitors, as monotherapy or in combination, demonstrate efficacy in patients with aggressive mTNBC.
- Current combination strategies face challenges, necessitating further investigation.
Conclusions:
- PD-1/PD-L1 inhibitors represent a valuable therapeutic approach for mTNBC.
- Continued research into novel immunotherapy regimens is crucial for future breakthroughs in mTNBC treatment.
